Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated by Analysts at JMP Securities

JMP Securities began coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a report released on Tuesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $17.00 target price on the stock.

Several other research firms have also recently weighed in on ZVRA. Cantor Fitzgerald reaffirmed an overweight rating on shares of Zevra Therapeutics in a research report on Wednesday, August 14th. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a buy rating for the company in a report on Wednesday, September 18th. HC Wainwright boosted their target price on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a buy rating in a report on Friday, September 20th. William Blair upgraded shares of Zevra Therapeutics to a strong-buy rating in a research note on Friday, August 30th. Finally, Maxim Group boosted their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a buy rating in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of Buy and an average price target of $21.00.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock opened at $6.92 on Tuesday. The company has a market cap of $364.13 million, a PE ratio of -5.13 and a beta of 1.94. The business has a 50 day moving average of $7.16 and a 200 day moving average of $5.76. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.95. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same quarter last year, the company posted ($0.15) earnings per share. As a group, equities research analysts forecast that Zevra Therapeutics will post -1.59 earnings per share for the current year.

Insider Activity at Zevra Therapeutics

In other news, Director Thomas Anderson purchased 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, July 16th. The stock was bought at an average price of $6.81 per share, with a total value of $68,100.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at $136,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have bought 22,000 shares of company stock valued at $140,340. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ZVRA. Jump Financial LLC bought a new position in Zevra Therapeutics during the fourth quarter valued at approximately $217,000. Armistice Capital LLC purchased a new stake in Zevra Therapeutics during the 4th quarter valued at $1,755,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after buying an additional 17,557 shares during the period. Virtu Financial LLC bought a new stake in shares of Zevra Therapeutics in the fourth quarter worth $177,000. Finally, Focus Financial Network Inc. ADV purchased a new stake in Zevra Therapeutics during the fourth quarter valued at $141,000. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.